A Fouse-ian debut
Jackie Fouse is the former CFO and president of Celgene, so she’s no stranger to the podium chats and investor scrums that define the JPM experience. But bright and early Monday morning, Fouse gets to check off one more item from the JPM bucket-list: Present for the first time as the CEO of Agios Pharmaceuticals.
As STAT's Adam Feuerstein reports, Fouse is unveiling a new six-year plan for Agios to double the number of approved medicines it sells from two to four, while also expanding into new indications and deepening its pipeline. Fouse will also use her financial acumen to trim Agios’ spending with the goal of becoming cash-flow positive by the end of 2025.
“Agios has accomplished a lot in 10 years, so this is not a situation where things are broken and I need to fix them,” said Fouse “I want to allow the foundational science of this company and its commitment to patients continue to take us places, but we need to be more disciplined and focused.”
Read more.
As STAT's Adam Feuerstein reports, Fouse is unveiling a new six-year plan for Agios to double the number of approved medicines it sells from two to four, while also expanding into new indications and deepening its pipeline. Fouse will also use her financial acumen to trim Agios’ spending with the goal of becoming cash-flow positive by the end of 2025.
“Agios has accomplished a lot in 10 years, so this is not a situation where things are broken and I need to fix them,” said Fouse “I want to allow the foundational science of this company and its commitment to patients continue to take us places, but we need to be more disciplined and focused.”
Read more.
No hay comentarios:
Publicar un comentario